Evidence map›Paper›PMID 36141897›Full record

ReviewInternational journal of environmental research and public health2022

SARS-CoV-2 Seroprevalence in Those Utilizing Public Transportation or Working in the Transportation Industry: A Rapid Review.

Aliisa Heiskanen, Yannick Galipeau, Marc-André Langlois, Julian Little, Curtis L Cooper

Abstract readReview
In one paragraph

Review in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aliisa HeiskanenSchool of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Yannick GalipeauDepartment of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Marc-André LangloisDepartment of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0003-4652-3029
Julian LittleSchool of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0001-5026-5531
Curtis L CooperSchool of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-3368-3499

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proximity and duration of social contact while working or using public transportation may increase users' risk of SARS-CoV-2 exposure. This review aims to assess evidence of an association between use of public transportation or work in the transportation industry and prevalence of SARS-CoV-2 antibodies as well as to identify factors associated with seropositivity in transit users. A literature search of major databases was conducted from December 2019 to January 2022 using key worlds including "seroprevalence", "SARS-CoV-2", and "public transit". A narrative review of included studies was completed for the following categories: those working in the transportation industry, healthcare workers relying on public transit, and population-based studies. The association between work in the transit industry and seroprevalence varied based on location, demographic characteristics, and test sensitivities. No association was found in healthcare workers. Several population-based studies indicated higher seroprevalence in those using public transit. Overall seroprevalence estimates varied based on geographic location, population demographics, study methodologies, and calendar date of assessment. However, seropositivity was consistently higher in racial minorities and low-income communities.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHealth PersonnelHumansSeroepidemiologic StudiesAntibodies, ViralCOVID-19public transitSARS-CoV-2seroprevalencetransportation

Identifiers

PMID36141897
PMCPMC9517055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.